The Conference Forum has announced the 9th annual Patients as Partners® Europe event, scheduled for May 20-21, 2025, at the Royal National Hotel ...

Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Dupixent, or Dupilumab, is an FDA-approved monoclonal antibody ... The product operates on key inflammation pathways in relation to EoE, including reducing the level of eosinophils count and ...

GSK plc GSK recently announced that EMA has accepted the regulatory filing seeking approval for its IL-5 inhibitor depemokimab in two respiratory indications – asthma with type II inflammation and ...

This inflammation pathway affects most patients with difficult ... In September, the FDA expanded Dupixent’s label in the CRSwNP indication for use in adolescent patients aged 12 to 17 years.

Want to apply for Canada PR? The country is set to introduce four new permanent residency (PR) pathways in 2025, even as the government plans to reduce its PR targets from 485,000 to 465,000, ...

Dupilumab, by binding to IL-4Rα, can inhibit the activation of the JAK/STAT6 signaling pathway by IL-4 and IL-13, thus blocking the aforementioned downstream inflammatory processes. EO, eosinophils; ...

However, biologics like Dupixent (dupilumab) have paved the way for a new treatment paradigm, targeting specific inflammatory pathways to reduce exacerbations and improve patient outcomes.

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Dupixent’s success has highlighted the potential of biologics to target specific inflammatory pathways in COPD, a space previously dominated by inhaled therapies. AstraZeneca’s Fasenra ...